Pier 88 Investment Partners LLC Increases Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Pier 88 Investment Partners LLC grew its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 7.0% in the third quarter, HoldingsChannel reports. The firm owned 121,610 shares of the company’s stock after buying an additional 7,910 shares during the quarter. Pier 88 Investment Partners LLC’s holdings in Pyxis Oncology were worth $446,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PYXS. Fullcircle Wealth LLC purchased a new position in shares of Pyxis Oncology in the 2nd quarter worth $40,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter worth about $59,000. The Manufacturers Life Insurance Company bought a new position in Pyxis Oncology during the 2nd quarter valued at about $65,000. Cetera Advisors LLC purchased a new stake in Pyxis Oncology in the 1st quarter worth about $100,000. Finally, Schulhoff & Co. Inc. lifted its stake in Pyxis Oncology by 90.9% in the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares during the last quarter. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PYXS. Stifel Nicolaus assumed coverage on Pyxis Oncology in a report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective for the company. Stephens began coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, September 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, August 16th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $9.57.

Pyxis Oncology Trading Down 7.4 %

Shares of Pyxis Oncology stock opened at $4.28 on Thursday. Pyxis Oncology, Inc. has a one year low of $1.35 and a one year high of $6.85. The company has a 50-day simple moving average of $3.65 and a two-hundred day simple moving average of $3.65.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. As a group, sell-side analysts anticipate that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current year.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.